Candesartan for the treatment of hypertension and heart failure

Bibliography

• STEWART S, MACINTYRE K, CAPE WELL S, MCMURRAY JJV: Heart failure and the aging population: an increasing burden in the 21st century? Heart (2003) 89(1):49–53.
   PubMed Web of Science ®Google Scholar
• GARG R, YUSUF S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JA/VIA (1995) 273(18):1450–1456.
   Google Scholar
• CIBIS-II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353(9146):9–13.
   PubMed Web of Science ®Google Scholar
• MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353(9169):2001–2007.
   PubMed Web of Science ®Google Scholar
• PACKER M, COATS AJS, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl. I Med. (2001) 344(22):1651–1658.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl. I Med. (1999) 341(10):709–717.
   PubMed Web of Science ®Google Scholar
• THE DIGITALIS INVESTINGATION GROUP: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl. Med. (1997) 336(8):525–533.
   PubMed Web of Science ®Google Scholar
• RICH MW: Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J. Am. Ger. Soc. (1997) 45(8):968–974.
   PubMed Web of Science ®Google Scholar
• REDFIELD MM: Heart failure - An epidemic of uncertain proportions. N Engl. J Med. (2002) 347(18):1442–1444.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA K, NAKA T, CHATANI F, YOSHIMURA Candesartan cilexetil: A review of its preclinical pharmacology. J Hum. Hypertens. (1997) 11(2 Suppl.):S9–S17.
   Google Scholar
• OJIMA M, INADA Y, SHIBOUTA Y et al.: Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur. Pharmacol. (1997) 319(1):137–146.
   PubMed Web of Science ®Google Scholar
• EASTHOPE S E, JARVIS B: Candesartan cilexitil. An update of its use in essential hypertension. Drugs (2002) 62(8):1253–1287.
   Google Scholar
• LACOURCIERE Y, ASMAR R: A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am. Hypertens. (1999) 12:1181–1187.
   PubMed Web of Science ®Google Scholar
• MANOLIS AJ, GROSSMAN E, JELAKOVIC B et al.: Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Ther. (2000) 22(10):1186–1203.
   Google Scholar
• BAKRIS G, GRADMAN A, REIF M et al.: Antihypertensive efficacy of candesartan in comparison to losartan: the claim study. .1 Clin. Hypertens. (Greenwich) (2001) 28;3(1):16–21.
   Google Scholar
• VIDT DG, WHITE WB, RIDLEY E et al.: A forced titration study of antihypertensive efficacy of candesartan cilexitil in comparison to losartan: CLAIM Study I. .1 Hum. Hypertens. (2001) 15(7):475–480.
   Google Scholar
• CUSPIDI C, MUIESAN ML, VALAGUSSA L et al.: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. Hypertens. (2002) 20(11):2293–2300.
   Web of Science ®Google Scholar
• MOGENSEN CE, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. (2000) 321(7274):1440–1444.
   PubMed Web of Science ®Google Scholar
• ROSSING K, JACOBSEN P, PIETRASZEK L, PARVING HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care (2003) 26(8):2268–2274.
   PubMed Web of Science ®Google Scholar
• LITHELL H, HANSSON L, SKOOG I et al.: The study on cognition and prognosis in the elderly (SCOPE): Principal results of a randomized double-blind intervention trial. Hypertens. (2003) 21(5):875–886.
   Web of Science ®Google Scholar
• LINDHOLM LH, PERSSON M, ALAUPOVIC et al.: Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). Hypertens. (2003) 21(8):1563–1574.
   Web of Science ®Google Scholar
• MCKELVIE R, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril and their combination in CHF Randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation (1999) 100:1056–1064.
   PubMed Web of Science ®Google Scholar
• MCKEL VIE RS, ROULEAU JL, WHITE M et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Ear: Heard. (2003) 24(19):1727–1734.
   Google Scholar
• GRANGER CB, ERTL G, KUCH J et al: Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heard. (2000) 139(4):609–617.
   PubMed Web of Science ®Google Scholar
• RIEGGER GAJ, BOUZO H, PETR P et al.: for the Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation (1999) 100:2224–2230.
   Google Scholar
• PFEFFER M, SWEDBERG K, GRANGER C et al.: for the CHARM INVESTIGATORS AND COMMITTEES: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet (2003) 362:759–766.
   PubMed Web of Science ®Google Scholar
• GRANGER C, MCMURRAY J, YUSUF S et al., for the CHARM INVESTIGATORS AND COMMITTEES: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet (2003) 362:767–771.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, OSTERGREN J, SWEDBERG K et al., for the CHARM INVESTIGATORS AND COMMITTEES: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet (2003) 362:772–776.
   PubMed Web of Science ®Google Scholar
• YUSUF S, PFEFFER M, SWEDBERG K et al, for the CHARM INVESTIGATORS AND COMMITTEES: Effects of candesartan in patients with chronic heart failure and left ventricular ejection fraction above 40%: the CHARM-Preserved Trial. Lancet (2003) 362:777–7816.
   PubMed Web of Science ®Google Scholar
• MCMURRAY J, OSTERGREN J, PFEFFER M et al., on behalf of the CHARM COMMITTEES AND INVESTIGATORS: Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart Failure — Assessment of Reduction in Mortality and Morbidity (CHARM) Programme. Ear: .1. Heart Failure (2003) 5:261–270.
   Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl. I Med. (1991) 325(5):293–302.
   PubMed Web of Science ®Google Scholar
• COHN J, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in CHF N Engl. I Med. (2001) 345(23):1667–1675.
   Google Scholar
• LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl. J. Med. (2001) 345(12):851–860.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. J. Med. (2001) 345(12):861–869.
   Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):995–1003.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial — the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355(9215):1582–1587.
   PubMed Web of Science ®Google Scholar
• YUSUF S, GERSTEIN H, HOOGWERF B et al.: Ramipril and the development of diabetes. "AMA (2001) 286(15):1882–1885.
   PubMed Web of Science ®Google Scholar
• ALLHAT OFFICERS AND COORDINATORS, for the ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). "AMA (2000) 288(23):2981–2997.
   Web of Science ®Google Scholar